Drug intelligence / Profile preview

Otibiome

Development stage: Preclinical
Lead developer: Zinereo Pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Otibiome is a probiotic food supplement developed by Zinereo Pharma, a Spanish biotechnology company specializing in the development and manufacture of probiotics and vaccines. Positioned within the company's respiratory health pipeline, Otibiome is designed to prevent upper respiratory tract infections (URTIs) and ear infections, such as otitis media, by promoting a healthy microbiome in the oral and pharyngeal cavities. The formulation typically utilizes beneficial bacterial strains, such as *Streptococcus salivarius*, which colonize the mucosal surfaces and inhibit the growth of pathogenic bacteria through competitive exclusion and the production of bacteriocin-like inhibitory substances (BLIS). It is primarily intended for use in pediatric and adult populations prone to recurrent respiratory infections.

Brand names: Otibiome
Other names: Otibiome

Beyond the preview

Go deeper on Otibiome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otibiome.

Explore the full profile